Exact Sciences (EXAS) News Today $48.92 -0.59 (-1.20%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Exact Sciences' (EXAS) Outperform Rating Reaffirmed at William BlairWilliam Blair reiterated an "outperform" rating on shares of Exact Sciences in a report on Thursday.February 21 at 12:17 PM | marketbeat.comExact Sciences (NASDAQ:EXAS) Shares Gap Down After Analyst DowngradeExact Sciences (NASDAQ:EXAS) Shares Gap Down Following Analyst DowngradeFebruary 21 at 10:40 AM | marketbeat.comExact Sciences (NASDAQ:EXAS) Price Target Cut to $65.00 by Analysts at BarclaysBarclays dropped their price target on Exact Sciences from $70.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday.February 21 at 8:09 AM | marketbeat.comExact Sciences (NASDAQ:EXAS) Given New $65.00 Price Target at Bank of AmericaBank of America lowered their price objective on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating for the company in a research report on Thursday.February 21 at 8:09 AM | marketbeat.comExact Sciences (EXAS) Receives a Buy from Piper SandlerFebruary 21 at 4:26 AM | markets.businessinsider.comExact Sciences Co. (NASDAQ:EXAS) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. cut its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 22.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 808,515 shares of the medical research company's stock after selling 240,741 shares during the period.February 21 at 3:53 AM | marketbeat.comWhy Exact Sciences (EXAS) Shares Are Trading Lower TodayFebruary 20 at 10:17 PM | msn.comExact Sciences (NASDAQ:EXAS) Issues Earnings ResultsExact Sciences (NASDAQ:EXAS - Get Free Report) released its quarterly earnings results on Wednesday. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%.February 20 at 4:55 PM | marketbeat.comExact Sciences (EXAS) Receives a Buy from CitiFebruary 20 at 8:16 AM | markets.businessinsider.comExact Sciences price target lowered to $65 from $75 at BTIGFebruary 20 at 8:16 AM | markets.businessinsider.comExact Sciences (EXAS) Q4 2024 Earnings Call TranscriptFebruary 20 at 8:16 AM | msn.comC2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Makes New $478,000 Investment in Exact Sciences Co. (NASDAQ:EXAS)C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 8,508 shares of the medFebruary 20 at 4:28 AM | marketbeat.comExact Sciences stock falls despite Q4 earnings beatFebruary 19 at 10:28 PM | in.investing.comExact Sciences says plans to launch three new cancer tests in 2025February 19 at 10:28 PM | markets.businessinsider.comExact Sciences reports Q4 EPS ($4.67), consensus (19c)February 19 at 10:28 PM | markets.businessinsider.comExact Sciences sees 13% screening growth in 2025 with new diagnostics launchesFebruary 19 at 10:28 PM | msn.comExact Sciences’s (NASDAQ:EXAS) Q4: Beats On RevenueFebruary 19 at 10:28 PM | finance.yahoo.comExact Sciences Corporation (EXAS) Q4 2024 Earnings Call TranscriptFebruary 19 at 9:01 PM | seekingalpha.comExact Sciences Corporation 2024 Q4 - Results - Earnings Call PresentationFebruary 19 at 6:28 PM | seekingalpha.comExact Sciences Announces Fourth Quarter 2024 ResultsFebruary 19 at 4:05 PM | businesswire.comExact Sciences (EXAS) Reports Earnings Tomorrow: What To ExpectFebruary 18 at 6:10 PM | msn.comU.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of a Second Patent Asserted by Exact SciencesFebruary 18 at 7:05 AM | businesswire.comExact Sciences Co. (NASDAQ:EXAS) Shares Sold by Peregrine Capital Management LLCPeregrine Capital Management LLC lessened its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 4.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 729,740 shares of the medical research compFebruary 18 at 6:13 AM | marketbeat.comBaillie Gifford & Co. Sells 196,774 Shares of Exact Sciences Co. (NASDAQ:EXAS)Baillie Gifford & Co. lowered its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 16.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,012,727 shares of the medical research company's stockFebruary 18 at 4:49 AM | marketbeat.comVan ECK Associates Corp Sells 13,023 Shares of Exact Sciences Co. (NASDAQ:EXAS)Van ECK Associates Corp decreased its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 9.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 122,842 shares of the medical research company's sFebruary 18 at 3:26 AM | marketbeat.comAlphaCentric Advisors LLC Sells 18,210 Shares of Exact Sciences Co. (NASDAQ:EXAS)AlphaCentric Advisors LLC lessened its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 60.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,790 shares of the medical research company's stock after sellinFebruary 17, 2025 | marketbeat.comExact Sciences (EXAS) Expected to Announce Quarterly Earnings on WednesdayExact Sciences (NASDAQ:EXAS) will be releasing earnings after the market closes on Wednesday, February 19, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=661502)February 17, 2025 | marketbeat.comEmpire Life Investments Inc. Decreases Holdings in Exact Sciences Co. (NASDAQ:EXAS)Empire Life Investments Inc. trimmed its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 2.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 242,765 shares of the medical research company'February 16, 2025 | marketbeat.comQuantum Private Wealth LLC Sells 16,499 Shares of Exact Sciences Co. (NASDAQ:EXAS)Quantum Private Wealth LLC reduced its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 26.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,775 shares of the medical research company's stock after selFebruary 16, 2025 | marketbeat.comBanque Pictet & Cie SA Has $3.97 Million Stake in Exact Sciences Co. (NASDAQ:EXAS)Banque Pictet & Cie SA trimmed its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 62.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 70,693 shares of the medical research company's stoFebruary 15, 2025 | marketbeat.com8,508 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital AdvisorsC2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,508 shares of thFebruary 14, 2025 | marketbeat.comExact Sciences downgraded to Mixed from Positive view at OTR GlobalFebruary 11, 2025 | markets.businessinsider.comSumitomo Mitsui Trust Group Inc. Lowers Position in Exact Sciences Co. (NASDAQ:EXAS)Sumitomo Mitsui Trust Group Inc. lowered its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 10.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 944,961 shares of the medical reseaFebruary 11, 2025 | marketbeat.comWhen Can We Expect A Profit From Exact Sciences Corporation (NASDAQ:EXAS)?February 10, 2025 | uk.finance.yahoo.comabrdn plc Has $3.46 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)abrdn plc increased its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 843.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,641 shares of the medical researchFebruary 10, 2025 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Holdings Lifted by Thompson Investment Management Inc.Thompson Investment Management Inc. grew its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 17.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 241,774 shares of the medical research company's stock afteFebruary 9, 2025 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Shares Sold by EULAV Asset ManagementEULAV Asset Management lessened its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 6.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 285,000 shares of the medical research company's stock after sellingFebruary 8, 2025 | marketbeat.comJennison Associates LLC Lowers Position in Exact Sciences Co. (NASDAQ:EXAS)Jennison Associates LLC trimmed its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 13.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 762,736 shares of the medical research company's stock aftFebruary 5, 2025 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Stake Boosted by Chicago Capital LLCChicago Capital LLC raised its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 126.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,080 shares of the medical research company'sFebruary 4, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Has $2.10 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)Robeco Institutional Asset Management B.V. lifted its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 37.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,286 shares of the medical research company's stock aftFebruary 4, 2025 | marketbeat.comExact Sciences Schedules Fourth Quarter 2024 Earnings CallFebruary 3, 2025 | businesswire.comSwedbank AB Purchases 13,333 Shares of Exact Sciences Co. (NASDAQ:EXAS)Swedbank AB boosted its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 76.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,848 shares of the medical research company's stock after buying an additionalFebruary 3, 2025 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Receives Average Recommendation of "Moderate Buy" from AnalystsExact Sciences Co. (NASDAQ:EXAS - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nineteen analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eighteen have isFebruary 2, 2025 | marketbeat.comGagnon Securities LLC Acquires 12,621 Shares of Exact Sciences Co. (NASDAQ:EXAS)Gagnon Securities LLC raised its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 5.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 246,204 shares of the medical research company's stock afterFebruary 1, 2025 | marketbeat.comBaader Bank Aktiengesellschaft Invests $4.33 Million in Exact Sciences Co. (NASDAQ:EXAS)Baader Bank Aktiengesellschaft bought a new position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 77,053 shares of the medical research company's stock, valued at apprJanuary 30, 2025 | marketbeat.comSlow Capital Inc. Purchases 5,346 Shares of Exact Sciences Co. (NASDAQ:EXAS)Slow Capital Inc. raised its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 7.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 82,001 shares of the medical research company's stock after buJanuary 28, 2025 | marketbeat.comExact Sciences: Liquid Biopsy Threat Is SolidifyingJanuary 27, 2025 | seekingalpha.comExact Sciences initiated with an Overweight at BarclaysJanuary 24, 2025 | markets.businessinsider.comBarclays Initiates Coverage of Exact Sciences (EXAS) with Overweight RecommendationJanuary 24, 2025 | msn.comExact Sciences Co. (NASDAQ:EXAS) Shares Sold by Beacon Investment Advisory Services Inc.Beacon Investment Advisory Services Inc. lowered its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 79.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,005 shares of the medical research company's stock after selling 26,9January 24, 2025 | marketbeat.com Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Media Mentions By Week EXAS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXAS News Sentiment▼0.490.60▲Average Medical News Sentiment EXAS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXAS Articles This Week▼359▲EXAS Articles Average Week Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Biogen News United Therapeutics News Incyte News BioMarin Pharmaceutical News Neurocrine Biosciences News Exelixis News Repligen News Halozyme Therapeutics News Madrigal Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXAS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
